Compare MAT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAT | CRSP |
|---|---|---|
| Founded | 1945 | 2013 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.7B |
| IPO Year | 1994 | 2016 |
| Metric | MAT | CRSP |
|---|---|---|
| Price | $17.41 | $54.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | $21.00 | ★ $70.00 |
| AVG Volume (30 Days) | ★ 6.2M | 1.6M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.33 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $5,379,546,000.00 | $289,590,000.00 |
| Revenue This Year | $5.73 | $1,603.19 |
| Revenue Next Year | $5.66 | $78.75 |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $13.95 | $30.06 |
| 52 Week High | $22.48 | $78.48 |
| Indicator | MAT | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 54.88 |
| Support Level | $14.75 | $46.48 |
| Resistance Level | $22.48 | $54.44 |
| Average True Range (ATR) | 0.77 | 2.76 |
| MACD | -0.42 | 0.60 |
| Stochastic Oscillator | 33.35 | 98.88 |
Mattel manufactures and markets toy products that are sold to its wholesale and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2024, with the remainder stemming from international markets.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.